Caribou Biosciences【CRBU】銘柄情報

Caribou Biosciences Inc (CRBU) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

1.66

( 1.22% )

買値

1.32

売値

1.98

出来高

2,539,799

1.57 日の範囲 1.70

1.12 52 週間の範囲 3.52

時価総額

164.64M

前日終値

1.64

始値

1.66

時刻

1.6495

最終取引時間

財務取引量

US$ 4,094,238

VWAP

1.612

平均取引量 (3 か月)

US$ 1,549,503

発行済株式数

99,180,575

配当利回り

PER

-1.19

1 株当たり利益 (EPS)

-1.41

歳入

11.2M

純利益

-133.22M

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing o... Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

cariboubio.com

本社

Berkeley, United States

設立

2026

Caribou Biosciences Inc is listed in the Healthcare sector of the ナスダック市場 with ticker CRBU. The last closing price for Caribou Biosciences was US$1.64. Over the last year, Caribou Biosciences shares have traded in a share price range of US$ 1.12 to US$ 3.52.

Caribou Biosciences currently has 99,180,575 shares in issue. The market capitalisation of Caribou Biosciences is US$164.64 million. Caribou Biosciences has a price to earnings ratio (PE ratio) of -1.19.

Form 8-K - Current report

After CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune Cell

Issued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a...

Form 8-K - Current report

Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026

-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and...

Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting

-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r...

Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting

BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading...

Form 8-K - Current report

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.14	-7.77777777778	1.8	1.825	1.59	2102548	1.64845978	CS
4	-0.31	-15.7360406091	1.97	2.49	1.59	1862150	1.98712586	CS
12	-0.18	-9.78260869565	1.84	2.49	1.59	1613693	2.02716752	CS
26	0.03	1.84049079755	1.63	2.49	1.39	1375715	1.89243185	CS
52	0.5	43.1034482759	1.16	3.52	1.12	1621300	2.00492784	CS
156	-2.69	-61.8390804598	4.35	8.5899	0.66	1723029	3.31335668	CS
260	-15.99	-90.5949008499	17.65	32.645	0.66	1307406	4.87928135	CS